Advanced diagnostic imaging, including Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET), provides direct, in vivo visualization of vector biodistribution and target engagement within nonhuman primate (NHP) models. This capability is fundamental for de-risking central nervous system (CNS) programs by confirming precise delivery to intended anatomical structures, thereby generating a more robust data package for multi-jurisdictional IND, IMPD, and other global regulatory submissions. Franklin Biolabs leverages these techniques to reduce study variability and accelerate timelines for next-generation therapies.

Frequently Asked Questions

Q: How does advanced imaging in NHP models support IND-enabling toxicology studies for CNS-targeted therapies?

Advanced imaging provides direct, non-invasive confirmation of vector delivery to the target anatomical region. Techniques like MRI-guided stereotactic injection verify accurate administration, while PET scans can visualize metabolic activity or receptor occupancy. This minimizes variability between subjects and provides definitive evidence of target engagement, strengthening the toxicology and biodistribution data required for regulatory submissions under GxP conditions.

Q: What is the translational relevance of using MRI-guided delivery in preclinical NHP studies?

Utilizing MRI-guided delivery in NHP models directly mirrors the procedural precision increasingly used in clinical settings. This approach ensures that the preclinical data on vector tropism, expression, and safety is generated from a highly accurate and reproducible delivery method. This alignment between preclinical and clinical procedures reduces translational gaps and provides higher confidence in the therapeutic candidate’s profile ahead of human trials.

Q: Can imaging data help refine the study design for next-generation therapies targeting the brain?

Yes. Imaging data offers an in-life view of vector performance that can inform decisions. For example, observing non-target tissue biodistribution via imaging can help adjust dosing strategies or administration routes in subsequent cohorts. This iterative, data-driven approach allows for the refinement of the therapeutic strategy well before committing to a final study design for pivotal GxP toxicology programs.

Technical Applications of Advanced Imaging for CNS Programs

Evaluating next-generation therapies targeting the central nervous system requires anatomical precision that cannot be adequately confirmed through post-mortem analysis alone. Direct, in vivo visualization of vector biodistribution, target engagement, and subsequent physiological response is a requirement for building a robust data package for global regulatory bodies, including those adhering to International Council for Harmonisation (ICH) guidelines.

Advanced diagnostic imaging modalities, such as MRI and PET, are integrated into our NHP programs to provide this confirmation. These techniques offer a non-invasive window into biological activity, enabling a more accurate assessment of a therapeutic candidate’s behavior in a translationally relevant large animal model.

MRI-Guided Stereotactic Administration

For therapies requiring direct injection into specific brain nuclei or structures, precision is a primary objective. Our teams utilize MRI-guided frameless stereotactic systems to administer viral vectors, such as AAVs carrying therapeutic payloads, with real-time anatomical verification.

This methodology offers distinct advantages:
* Confirmed Target Engagement: Real-time imaging confirms the injection cannula is correctly placed, ensuring the vector is delivered to the intended target, such as deep cerebellar nuclei or other specific structures.
* Reduced Study Variability: By removing the uncertainty associated with atlas-based coordinates, MRI guidance ensures consistent and accurate delivery across all animals in a study cohort, leading to more reliable and interpretable data.
* Enhanced Translational Value: The technical note on MRI-guided injections (PMID: 38310346) underscores the feasibility and safety of this approach, demonstrating its value in generating clinically relevant data for preclinical gene therapy evaluation. This level of precision directly informs human trial design.

This procedural control is supported by our more than 100,000 square feet of flexible animal facility space, designed to accommodate complex procedures and long-term observation. The ability to confirm delivery and monitor biodistribution in vivo is a key component of the infrastructure required to support these programs. [FBL-VID-04]

PET Imaging for Functional Assessment

Beyond anatomical delivery, understanding the functional consequences of a therapy is a core objective. PET imaging allows for the quantitative assessment of biological processes in vivo. By using specific radiotracers, PET scans can measure:
* Metabolic activity in target tissues.
* Receptor occupancy and density.
* Cellular proliferation or inflammation.

This functional data provides a dynamic view of a therapy’s mechanism of action and physiological impact over time. When combined with MRI for anatomical context, a comprehensive picture of the therapeutic candidate’s in vivo profile emerges. This integrated approach is central to our work in Preclinical and Translational Services and supports our mission of minimizing clinical risk. The track record of our founding scientific leadership and core team, which includes a 100% successful IND rate since 2019, was built on this type of rigorous, data-driven science, a legacy we continue since our formal launch in 2024.